Charles River Laboratories International (CRL) Saham Harga

Charles River Laboratories International Inc is primarily active in the life sciences industry.

Some of the main competitors of Charles River Laboratories International Inc in the market include Covance Inc., Envigo, PPD, Eurofins Scientific, and LabCorp.

Charles River Laboratories International Inc is a renowned company in the field of preclinical and clinical laboratory services. Founded in 1947, Charles River has built a strong reputation as a trusted provider of comprehensive research support. With a focus on helping pharmaceutical and biotechnology companies bring new drugs to market, they offer a wide range of services including drug discovery, safety assessment, and manufacturing support to clients worldwide. The company's expertise in advanced animal models, laboratory sciences, and support services has propelled it to the forefront of the life sciences industry. Today, Charles River Laboratories continues to play a vital role in advancing much-needed medical therapies.

Charles River Laboratories International Inc has achieved several significant milestones. It has consistently demonstrated strong financial performance, delivering consistent revenue growth and expanding its global footprint. The company has successfully completed strategic acquisitions, enabling it to enhance its capabilities and expand its service offerings. Charles River Laboratories International Inc has also received notable recognition, including being named one of the World's Most Ethical Companies for several consecutive years. Moreover, the company has been at the forefront of scientific advancements, collaborating with global pharmaceutical and biotechnology companies to develop innovative solutions that improve drug discovery and development processes.

Charles River Laboratories International Inc is primarily present in the following countries and regions: United States, Canada, Europe, Asia Pacific, and Latin America.

Charles River Laboratories International Inc represents various values and corporate philosophies. The company is committed to their mission of improving the lives of people and animals through innovative research and development. They aim to maintain the highest standards of scientific integrity, ethical conduct, and regulatory compliance. Charles River Laboratories prioritizes collaboration and partnership with their clients to provide comprehensive solutions and exceptional service. With a focus on quality, efficiency, and expertise, they strive to consistently deliver reliable and innovative scientific services and products. Through their dedication to responsible and sustainable practices, Charles River Laboratories aims to make a positive impact on society and the environment.

Analis saat ini menetapkan target harga rata-rata 267,60 USD untuk saham Charles River Laboratories International (median: 273,00 USD), yaitu -7,8 % terhadap harga terbaru. Konsensus didasarkan pada 23 peringkat analis.

Charles River Laboratories International Target Harga Analis 2026

23 analis saat ini menilai saham Charles River Laboratories International: 17 merekomendasikan beli, 6 tahan, dan 0 jual. Untuk 2026, analis memperkirakan Charles River Laboratories International menghasilkan pendapatan 3,91 miliar USD dan laba per saham 11,42 USD.

Charles River Laboratories International Target Harga Analis 2026

Dengan kurs saat ini, saham Charles River Laboratories International diperdagangkan pada 257,95 EUR (290,19 USD).

Saham Charles River Laboratories International (CRL) tercatat di 6 bursa, termasuk: NYSE (CRL), SIX (Zürich) (RV6.SW), XETRA (RV6.DE), Frankfurt (RV6.F), München (RV6.MU), Düsseldorf (RV6.DU).

Charles River Laboratories International Inc is a global leader in the field of life sciences, offering its customers a wide range of products and services. The company's business model is based on three main areas: research and development, preclinical services, and bioproducts. Research and Development: Charles River Laboratories offers a variety of services to support its customers in the development of new products. These include chemical and pharmacological screening systems, study design and planning, cell and tissue banking, genotoxicology, protein and antibody production, and much more. Charles River Laboratories has a comprehensive range of scientific and technical capabilities to assist its customers in the development of new drugs, biotechnology products, and medical devices. Preclinical Services: The company provides its customers with a wide range of preclinical services to test the safety and efficacy of products. These services include toxicology, pathology, pharmacology, bioanalytics, and clinical diagnostics. Charles River Laboratories has several preclinical research facilities worldwide and can support customers in the validation of new therapies and products. Bioproducts: Charles River Laboratories produces a variety of bioproducts for research and development, including cell lines, antibodies, nucleic acids, and proteins. The company also offers specialized services such as genetic manipulation and custom modification of cell lines to achieve specific research goals. The company focuses on customer loyalty and has earned the trust of customers by offering high-quality products and services. Charles River Laboratories has a global presence with facilities in North America, Europe, and Asia, and can serve customers worldwide. The company also maintains a strong partnership with the scientific community by supporting research initiatives and public health measures. Charles River Laboratories is committed to offering its customers a comprehensive range of services to meet their needs in the field of life sciences. The company is dedicated to continuously improving its research and development and introducing new services and products to meet the ever-changing needs of customers.

Pendapatan diperkirakan dari Charles River Laboratories International adalah 3,91 miliar USD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.

Laba diperkirakan dari Charles River Laboratories International adalah 561,96 Juta. USD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.

Rasio harga-terhadap-pendapatan (PER) Charles River Laboratories International saat ini adalah 25,41. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Charles River Laboratories International.

Rasio harga-terhadap-penjualan (PSR) Charles River Laboratories International saat ini adalah 3,66. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Charles River Laboratories International.

Skor Kualitas AlleAktien untuk Charles River Laboratories International adalah 3/10.

ISIN dari Charles River Laboratories International adalah US1598641074. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.

WKN dari Charles River Laboratories International adalah 939391. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.

Ticker dari Charles River Laboratories International adalah CRL. Simbol ticker digunakan untuk memperdagangkan saham Charles River Laboratories International di bursa saham.